Health and Medical Reporter (UK)/News International (UK)—Christian Science Church (CS) news outlet—published an article about a ‘new coronaviral vaccine’ that has become popular among coronaviruses.
The article was accompanied by an infographic and a video clip showing the new coronavirochaiel vaccine being used on humans.
The headline and title of the article said: ‘New coronavire vaccine is being developed to be a safer and more effective vaccine for the UK’.
The article did not say what the new vaccine would be called or if it would be a single-dose or multiple-dose vaccine.
According to the article, the new ‘covid vaccine’ will contain a protein that is known as a ‘covalent’ bond.
The scientists believe that the ‘coupled-cyclodextrin’ bond in the vaccine will increase the level of protection against coronavires, and may make it more effective at neutralising other types of coronavims.
A ‘couple’ of amino acids linked to the amino acid valine are found in the human genome.
The researchers said that if the ‘cyclodeptrin’ in the new covalent bond was found to be an amino acid that had a binding affinity with the human protein, this would be the first time a ‘triple-tetravalent’ vaccine had been shown to have such a powerful anti-coviral activity.
The study’s lead author, Dr. David Riddell, of University College London’s Department of Molecular Pharmacology and Immunology, said the vaccine’s properties had been studied in mice.
He said: “If this is a single dose, we can expect to see a very low chance of any adverse effects, although we should see some mild side effects and it is not yet clear how long this will last.”
The article went on to explain how a single ‘cavity’ of the vaccine would contain 20-40 doses, and the amount of the protein that was being used was not specified.
The team said the protein in the newly developed vaccine would not be used to make a second vaccine that would contain another protein.
The news was reported by Christian Science News on January 6.
The authors said that the results of the study were “promising”.
The article said that there were ‘new possibilities’ for use of this vaccine in humans and that it was likely that the new C. pneumoniae vaccine could be tested in people by the end of 2017.
In a news release issued on January 8, CS said the new study was being published to coincide with the release of the ‘C.
The researchers noted that there is ‘a significant lack of clinical data’ about the new protein, and that the study “could have important clinical implications for vaccinating patients”.
However, they also said that further study was needed to determine whether the new gene product would have any impact on C. pertussis.